Next-Step Treatment Considerations for Patients With Treatment-Resistant Depression That Responds to Low-Dose Intravenous Ketamine
Copyright © by the American Psychiatric Association..
Numerous short-term randomized trials support the acute-phase efficacy of low-dose intravenous (IV) ketamine for patients with treatment-resistant unipolar or bipolar depression. Ketamine's antidepressive effects generally have limited duration, highlighting the need for maintenance treatment after an acute-phase response. It is increasingly likely that psychiatrists will be called upon to manage the care of patients with treatment-resistant unipolar or bipolar depression who have responded acutely to ketamine and to recommend or initiate next-step treatments. However, there is a paucity of controlled evidence to guide best practices for managing treatment of patients with treatment-resistant unipolar or bipolar depression who have had a positive initial response to ketamine. This article reviews the available evidence supporting specific strategies for extending and maintaining acute antidepressive responses to low-dose IV ketamine in patients with treatment-resistant unipolar or bipolar depression and provides some preliminary considerations for clinical practice.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Focus (American Psychiatric Publishing) - 18(2020), 2 vom: 31. Apr., Seite 181-192 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bobo, William V [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bipolar depression |
|---|
| Anmerkungen: |
Date Revised 02.04.2021 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1176/appi.focus.20190048 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317306324 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317306324 | ||
| 003 | DE-627 | ||
| 005 | 20231225163006.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1176/appi.focus.20190048 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1057.xml |
| 035 | |a (DE-627)NLM317306324 | ||
| 035 | |a (NLM)33162856 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bobo, William V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Next-Step Treatment Considerations for Patients With Treatment-Resistant Depression That Responds to Low-Dose Intravenous Ketamine |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.04.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © by the American Psychiatric Association. | ||
| 520 | |a Numerous short-term randomized trials support the acute-phase efficacy of low-dose intravenous (IV) ketamine for patients with treatment-resistant unipolar or bipolar depression. Ketamine's antidepressive effects generally have limited duration, highlighting the need for maintenance treatment after an acute-phase response. It is increasingly likely that psychiatrists will be called upon to manage the care of patients with treatment-resistant unipolar or bipolar depression who have responded acutely to ketamine and to recommend or initiate next-step treatments. However, there is a paucity of controlled evidence to guide best practices for managing treatment of patients with treatment-resistant unipolar or bipolar depression who have had a positive initial response to ketamine. This article reviews the available evidence supporting specific strategies for extending and maintaining acute antidepressive responses to low-dose IV ketamine in patients with treatment-resistant unipolar or bipolar depression and provides some preliminary considerations for clinical practice | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a bipolar depression | |
| 650 | 4 | |a esketamine | |
| 650 | 4 | |a ketamine | |
| 650 | 4 | |a treatment-resistant depression | |
| 700 | 1 | |a Riva-Posse, Patricio |e verfasserin |4 aut | |
| 700 | 1 | |a Goes, Fernando S |e verfasserin |4 aut | |
| 700 | 1 | |a Parikh, Sagar V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Focus (American Psychiatric Publishing) |d 2010 |g 18(2020), 2 vom: 31. Apr., Seite 181-192 |w (DE-627)NLM225623528 |x 1541-4094 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2020 |g number:2 |g day:31 |g month:04 |g pages:181-192 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1176/appi.focus.20190048 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2020 |e 2 |b 31 |c 04 |h 181-192 | ||